Coach — Aspirin (The Kit)
Kit page: aspirin as weather on the board — eicosanoid quieting, platelet serotonin doors, mito windows — not a longevity meme and not a dosing card. Education only; no dosing.
The Kit · Sage · Surfer · Serotonin · Cardiac
Aspirin is usually argued about as a clot drug, an inflammation drug, or a cancer-prevention drug. For many people it is simply the bottle in the cabinet for a headache, or the small daily tablet someone once said was good for the heart. Those frames are not wrong. In the working hypothesis behind this essay, they are incomplete. Aspirin's lasting physiology looks more like an intervention in energy delivery: who gets oxygen and fuel, how hard mitochondria have to work, which fuels they are allowed to burn, and how the body handles serotonin outside the brain.
Safety first
Bleeding and stomach risk are not footnotes. Anyone taking an anticoagulant or another drug that affects clotting, anyone with a history of ulcers or bleeding, and anyone assembling a do-it-yourself prevention routine belongs with their own physician, not with an essay. If a physician has prescribed aspirin for a specific reason, nothing here should change that plan. Aspirin for children is not something to improvise, and neither is aspirin in pregnancy.
The extended report adds three points. On children and inherited weakness in fat burning: "Acetaminophen does not do this at all — one reason aspirin, not acetaminophen, is the Reye-associated drug." And later: "That paper is also the modern restatement of the Reye warning — if the FAO machinery is already genetically weak, the same push becomes a bottleneck." On antidepressants that act on serotonin: "Chronic SSRI use empties that store because SERT is the only refill pump." That store is the serotonin stored inside platelets, part of how they help blood clot, so the combination is one more reason medication questions belong with the prescribing physician.
Two molecules in one tablet
Aspirin is a short-lived acetylating agent attached to a long-lived acid. Once swallowed, enzymes in blood and liver split it within minutes. The acetyl group is transferred onto proteins, most famously onto a specific site in the enzyme cyclooxygenase, or COX, which it permanently disables. What remains is salicylate, which circulates for hours, longer at high doses because the body's clearance pathway saturates.
That split explains why low-dose aspirin and high-dose aspirin are not the same drug at different strengths. They are different pharmacologies that happen to share a bottle. The small antiplatelet amount works mainly through intact aspirin acting on platelets as they pass through the gut's blood supply. The large anti-inflammatory amounts, measured in grams, produce high salicylate levels, and almost every mitochondrial effect in the literature is a salicylate effect at that high end. Overdose is the same chemistry with the volume knob broken. Conflating these is how the literature talks past itself.
The fast clock: the eicosanoid telegram
COX turns a fatty acid released from cell membranes into a family of short-lived signaling molecules called eicosanoids. Platelets have only one form of COX and, having no nucleus, cannot make more. Once aspirin disables it, that platelet cannot make thromboxane, its main signal for clumping and for constricting nearby vessels, for the rest of its life of about a week to ten days. The cells lining blood vessels can make new COX, so their protective signal, prostacyclin, recovers while platelet thromboxane stays down. In the hypothesis this is the cleanest oxygen-delivery effect of low-dose aspirin: fewer platelet plugs in small vessels and less spasm.
Another eicosanoid, prostaglandin E2, interests the hypothesis more. It is not a clot molecule. It instructs immune cells, and in laboratory systems it tilts how they mature. An observational study found that regular aspirin after a colorectal cancer diagnosis was associated with longer survival only in patients whose tumors carried a particular mutation in a pathway that sits downstream of prostaglandin E2 receptors. The extended report is careful: that is a clue, not a closed case, and it has not been uniformly replicated. It is still hard to explain with "blood thinning" alone.
Aspirin also does something no other common anti-inflammatory copies. COX that aspirin has modified can still make a precursor that white blood cells convert into an "aspirin-triggered lipoxin," a molecule involved in resolving inflammation. In a randomized trial of healthy adults, that lipoxin rose at the lowest daily amount tested and not at the highest. In mice, part of aspirin's anti-inflammatory effect depends on nitric oxide. So some of low-dose "anti-inflammation" may be a story about resolution and blood-vessel signaling, not only about subtracting prostaglandins. The first layer of the hypothesis is not mitochondrial at all. It is a rewrite of the local chemical message that decides whether a small vessel stays open.
The slow clock: uncoupling, written as chemistry
Mitochondria make ATP by pumping protons across their inner membrane and letting them flow back through the ATP-making turbine. Anything that lets protons leak back another way is an uncoupler. The energy of burning fuel then leaves as heat rather than ATP, the chain speeds up to defend the membrane's charge, and oxygen use rises. Salicylate, at high concentration, is a weak version of the classic uncouplers, carrying protons into the matrix through an unusual feature of its structure. Aspirin itself does this weakly, and acetaminophen not at all.
The extended report draws the line clearly: "Mild uncoupling is not the same physiology as toxic uncoupling." A slight drop in the membrane's charge can reduce the backward electron flow that produces bursts of reactive oxygen, which is the argument made for the gentle leak of brown fat. A large drop collapses ATP, opens the cell's self-destruct pore, and kills the cell. Salicylate poisoning, with its fever, sweating, and mixed acid-base disturbance, is that collapse. Salicylate also partly blocks a key enzyme in the citric acid cycle, so the same molecule makes the membrane leakier while narrowing a gate in the cycle. That is not "more energy." It is a mitochondrion asked to run faster through a narrower door. In the hypothesis, those injury findings are reasons never to climb a dose, not invitations to push mitochondria harder, and no consumer use of aspirin is a controlled uncoupling tool.
Fuel choice and cellular cleanup
At high exposure, salicylate binds the energy sensor AMPK directly. That opens the gate that lets fat into mitochondria, limits the flood of fatty acids out of fat tissue, and in fat-precursor cells increases the building of new mitochondria. Work with the related drug salsalate complicated the picture usefully: some metabolic benefits survived removal of the relevant AMPK subunit, and what tracked them was a direct increase in proton leak. A leak raises energy demand. AMPK then helps decide which fuel meets it. In cell culture, very high aspirin exposure pushed cells to burn long-chain fat while fragmenting their mitochondrial network and slowing the chain, which the authors read as compensation for impairment, and which is the modern form of the Reye warning.
Salicylate also competes with acetyl-CoA at an enzyme called EP300, and blocking it releases the cell's recycling program, autophagy. In mice, worms, and heart tissue, aspirin increased that cleanup, including the removal of damaged mitochondria. That is why aspirin is sometimes called a caloric-restriction mimetic. It is the most plausible longevity biochemistry aspirin has, and it belongs to the high-exposure range, not to the small daily tablet. It remains hypothesis.
Serotonin as an operating system
About 95 percent of the body's serotonin is outside the brain. Almost all of it is made in the gut, released into the blood, and immediately taken up by platelets, which cannot make it themselves but store it at high concentration. What people call "blood serotonin" is almost entirely platelet serotonin. The essay on serotonin develops this as an operating system rather than a mood molecule.
When a platelet is activated, it releases its serotonin, which signals neighboring platelets to release more. That is a local amplifier, running in parallel with thromboxane. It is one reason so-called aspirin resistance can be a serotonin story: if the serotonin signal is loud, silencing thromboxane does not quiet the platelet. In people taking low-dose aspirin, higher serotonin tracked higher remaining platelet reactivity, and adding serotonin to blood samples restored it.
On the vessel wall, serotonin is a context-dependent switch. With healthy lining it can dilate. In diseased or plaque-lined arteries, including the coronaries discussed in the essay on the heart, it constricts and promotes clumping. In animal models of immune-complex shock and lung injury, platelet serotonin was required for the leak and the damage. In the gut it drives motility and reaches liver, fat, and pancreas, where it shapes fuel handling. And when platelets dock onto immune cells, serotonin is part of the cargo that instructs them, the seam between this essay and the one on the immune system. Brain serotonin is a separate pool. The only honest bridge between aspirin and mood runs through the shared supply of the amino acid tryptophan, not through platelet serotonin crossing into the brain.
Fuel and oxygen as one problem
Aspirin does not create oxygen delivery. It may change the inflammatory and vascular conditions that sit on top of delivery. If the foundation is poor, with seed oils, a flood of sugar, bright light late at night, and no recovery, any molecule looks louder and riskier. Food, discussed under fuel toxins, daily rhythm, and strength that pulses and then recovers change the conditions any drug lands in. "Take aspirin to fix your mitochondria" is not a conclusion this hypothesis supports.
The hypothesis is stated so it can be wrong. If the eicosanoid changes, the mitochondrial windows, and the serotonin doors fail to fit together, the story collapses back into ordinary anti-inflammatory folklore. The neighboring essays on sulindac and methylene blue apply the same scrutiny to other drugs with mitochondrial reach.
For the full argument, read the extended report on aspirin. The short version is in the lessons. Talk with your own physician before changing medications or supplements.
A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 17, 2026.